

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

WEHI-164

RRID:CVCL_2251

Type: Cell Line

Proper Citation

CLS Cat# 400438, RRID:CVCL_2251

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2251

Proper Citation: CLS Cat# 400438, RRID:CVCL_2251

Description: Cell line WEHI-164 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse fibrosarcoma

Defining Citation: [PMID:4543620](#), [PMID:9753870](#), [PMID:31220119](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: WEHI-164

Synonyms: WEHI 164, WEHI164, WEHI 164 TC

Cross References: CLO:CLO_0009567, CLO:CLO_0009573, CLDB:cl4680, CLDB:cl4681, CLDB:cl4683, ATCC:CRL-1751, BCRJ:0247, BioSample:SAMN11397634, CCRID:4201MOU-CCTCC00092, CCTCC:GDC0092, ChEMBL-Cells:ChEMBL3308344, ChEMBL-Targets:ChEMBL614227, CLS:400438, ECACC:87022501, ICLC:ATL96004, IZSLER:BS TCL 195, KCLB:21751, NCBI_Iran:C200, PubChem_Cell_line:CVCL_2251, Wikidata:Q54993747

ID: CVCL_2251

Vendor: CLS

Catalog Number: 400438

Record Creation Time: 20220624T071420+0000

Record Last Update: 20260830T000526+0000

Ratings and Alerts

No rating or validation information has been found for WEHI-164.

No alerts have been found for WEHI-164.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pfister SK, et al. (2026) Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies. Molecular cancer therapeutics, 25(2), 310.

Al Jawazneh A, et al. (2026) Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis. The Journal of experimental medicine, 223(7).

Wang Z, et al. (2026) Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma. Materials today. Bio, 39, 103386.